Healthcare / Medical DevicesTokyo
$2683.00
-6.00 (-0.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$88.4B
P/E
22.9x
↑EV/EBITDA
15.8x
↑ROE
5.1%
↑Gross Margin
40.7%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.9%
FCF CAGR
-38.9%
FCF margin
1.6%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.54B · net income $2.23B · FCF $655.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.54B | $40.54B | $40.05B | $43.27B | $43.00B |
| Net Income | $2.23B | $2.23B | $2.63B | $5.74B | $6.22B |
| EBITDA | $5.56B | $5.56B | $5.85B | $9.73B | $10.55B |
| EPS | 64.27 | 64.27 | 71.10 | 153.86 | 167.01 |
| Gross Margin | 40.7% | 40.7% | 41.8% | 47.4% | 47.8% |
| Operating Margin | 7.4% | 7.4% | 8.4% | 17.2% | 19.5% |
| Net Margin | 5.5% | 5.5% | 6.6% | 13.3% | 14.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 |
| Current Ratio | 2.19 | 2.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $655.0M | $655.0M | $1.72B | $4.30B | $2.88B |
| Returns | |||||
| ROE | 5.1% | 5.1% | 5.7% | 11.6% | 13.6% |
| Valuation | |||||
| P/E | 22.94 | 22.94 | 27.57 | 10.10 | 10.48 |
| EV/EBITDA | 15.75 | 15.75 | 10.37 | 4.51 | 5.05 |
| P/B | 2.13 | 2.13 | 1.58 | 1.17 | 1.42 |
| Growth & Yield | |||||
| Revenue Growth | 1.2% | 1.2% | -7.4% | 0.6% | — |
| EPS Growth | -9.6% | -9.6% | -53.8% | -7.9% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
54.7%
EPS terminal req.
$238.07
Spread vs growth
-64.3%
5Y implied EPS CAGR
35.0%
EPS terminal req.
$288.07
Spread vs growth
-44.6%
10Y implied EPS CAGR
21.9%
EPS terminal req.
$463.93
Spread vs growth
-31.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.3%
Start / end P/E
28.1x → 41.7x
EPS bridge
71.10 → 64.27
Residual
-4.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.